findmyKOL
Clinical trialNCT03093909RecruitingPhase 1Interventional

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

SponsorM.D. Anderson Cancer CenterEnrollment44Malignant Neoplasm of Bone and Articular CartilageMalignant Neoplasm of Male Genital OrgansMalignant Neoplasm of Respiratory and Intrathoracic Organ CarcinomaMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple SitesMalignant Neoplasms of Lip Oral Cavity and Pharynx+4 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have spread to the lungs from other parts of the body. The safety and side effects of this drug will also be studied. This is an investigational study. Gemcitabine is FDA approved and commercially available for the treatment of pancreatic and lung cancer, and other solid tumors. Its administration by inhalation is investigational. The study doctor can explain how the study drug is designed to work. Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • the University of Texas Md Anderson Cancer Center

    Houston, Texas, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gemcitabine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 Nov 2017
Primary completion
30 Nov 2027
Completion
30 Nov 2027
Last update posted
15 Jul 2026
Registered enrollment
44
Registry id
NCT03093909
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.